To Cure A Rose Foundation was founded by Casey McPherson, when he discovered his daughter Rose had a rare disease with no cure.
200 million children suffer from rare genetic diseases, and only 5% of those disease's have a therapeutic option. 30% of those children will die before their 5th birthday. Yesterday, most of these diseases would have cost hundreds of millions of dollars and over a decade to solve. Today, we have the technology to cure many of these diseases, but we don't have the funding, business models, pipelines, and efficiencies needed to do this at scale. To Cure A Rose Foundation is laser focused on creating a pathway for these children by revolutionizing the drug development process.
We rely on the support of generous donors - large and small, to fund the life changing work we do. Please reach out if you'd like to become apart of To Cure A Rose Foundation.
Company Details
- Employees
- 11
- Founded
- -
- Address
- 1401 Lavaca St,
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- http://www.tocurearose.org
- Keywords
- biotechnology, rare disease, drug development, antisense oligonucleotide, small molecule repurposing, gene therapy, disease modeling, genetics, ipsc, neurosience, neurodevelopmental, neurodegenerative.
- HQ
- Austin, Texas
To Cure A Rose Foundation Questions
To Cure A Rose Foundation's website is http://www.tocurearose.org
To Cure A Rose Foundation's LinkedIn profile is https://www.linkedin.com/company/to-cure-a-rose-foundation
To Cure A Rose Foundation has
11 employees.
View email and phone details for 11
employees at To Cure A Rose Foundation.
To Cure A Rose Foundation's industry is
Biotechnology Research
To Cure A Rose Foundation's top competitors are
Neurox1 Inc.,
Shiftrx,
Alpharose Therapeutics,
Veritas Innovation,
Neurobane,
Everlywell,
Everyone Medicines,
Perlara Pbc,
Everlume Bio,
Precigenetics.
To Cure A Rose Foundation's categories are Biotechnology Research
To Cure A Rose Foundation's founding year is 2021
